Merz Announces Key Governance Changes
Merz, a global leader in medical aesthetics and specialty neurology, announced today that Philip Burchard will be appointed Chairman of the company’s Shareholders Council. He will assume this role in addition to his current position as Chief Executive Officer of the Merz Healthcare Group. In his new position, Philip Burchard will succeed Andreas Krebs, who has decided to step down from his current roles as Chairman of the Shareholders Council and Supervisory Board of Merz in order to dedicate more time to his personal entrepreneurial and philanthropic activities. In addition, Dr. Christian Holzherr will be the new Chairman of the Merz Supervisory Board. All changes will be effective as of October 31, 2019.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190816005106/en/
Philip Burchard, CEO of Merz (Photo: Business Wire)
Philip Burchard joined Merz as CEO in July 2012. Under his leadership, Merz has focused its strategy on aesthetics and specialty neurology, leading to a realignment of its global R&D organization, the acquisitions of numerous companies in the aesthetics space, and successful geographic expansion in Latin America and Asia Pacific. Philip Burchard has more than 30 years of experience in the pharmaceutical industry, having worked in sales and marketing, as well as general management roles, in six different countries across Asia, Europe, Latin America and the United States.
“I am sincerely grateful to Andreas Krebs for his excellent support and strategic counsel over the past years,” said Philip Burchard, CEO of Merz. “Having worked side by side with Andreas, I have personally witnessed the way he has shaped the company and its transformation, growth and success. Following in his footsteps as Chairman of the Shareholders Council is a great honor.”
Andreas Krebs joined the Merz Shareholders Council in 2010 and has served as Chairman since 2012. In close collaboration with the management team, he championed and supported the evolution of Merz’s strategy, transforming the company into a leading global specialty healthcare company fully focused on aesthetics, specialty neurology and consumer care. In addition, Andreas Krebs has helped guide and advise the company through a number of major acquisitions and critical business situations.
“I am both proud and grateful to have played a significant role in the transformational journey of Merz over the past ten years. With all that we have accomplished together, it is now the right time for me to hand over the reins to Philip Burchard, who – I am confident – will excel in both his new and existing responsibilities. The Shareholders Council shares this view and is pleased to welcome Philip Burchard in his new role,” said Andreas Krebs, Chairman of the Shareholders Council of Merz.
The Merz family shareholders, who continue to be represented by Andreas Meyer and Christian Baatz in both the Shareholders Council and Supervisory Board for all key strategic decisions, also expressed sincere gratitude to Andreas Krebs.
“Andreas Krebs supported the Merz family during the handover of responsibilities to the fourth generation of the family shareholders, as well as the further evolution of our family holding structure. With remarkable loyalty, commitment and thoughtfulness he handled all business, strategic and personal matters very successfully and has always been a trusted advisor. We are extremely pleased with the tremendous progress made during the past decade, and we wish Andreas all the best for the next phase of his life,” said Andreas Meyer, shareholder of the Merz family and Vice Chairman of the Merz Healthcare Group Shareholders Council and Supervisory Board.
Dr. Christian Holzherr will become the new Chairman of the Supervisory Board of Merz Pharma GmbH & Co. KGaA, in addition to his current role as a member of the Shareholders Council. Dr. Holzherr is a highly experienced business executive with a track record in CEO and CFO positions in the pharmaceutical and medical device industries, as well as excellent experience working with family-owned companies. He is also Chairman of the Tax and Audit Committee and has been a member of the Supervisory Board since 2017.
About Merz
Merz is a global, family-owned aesthetics, specialty neurology and consumer care company based in Frankfurt, Germany. Privately-held for 110 years, the company is distinguished by its commitment to innovation, long-term perspective and focus on profitable growth. In addition to its comprehensive portfolio of medical aesthetics products across the device, injectable and skincare categories, Merz also develops neurotoxin therapy to treat neurologically-induced movement disorders. In fiscal year 2017/18, Merz generated revenue of EUR 1.024,4 million; the company has a total workforce of 3,151 employees worldwide and a direct presence in 28 countries. More information is available at www.merz.com.
Copyright © 2019 Merz Pharma GmbH & Co. KGaA. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190816005106/en/
Contact information
Merz Pharma GmbH & Co. KGaA
Global Communications
Dr. Elisa Antz
Phone: +49 69 1503 1265
Email: elisa.antz@merz.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new
MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release
The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin
IonQ Unanimously Appoints Peter Chapman as Next Chairman of the Board of Directors26.4.2024 13:30:00 CEST | Press release
IonQ (NYSE: IONQ), a leader in the quantum computing industry, announced today the appointment of Peter Chapman as its next Chairman of the Board and Harry You as the Lead Independent Director of the Board, effective at the close of IonQ’s upcoming Annual General Meeting on June 5, 2024. Both appointments were disclosed in a proxy statement issued on April 25, 2024. Peter Chapman has also been nominated for re-election as a Class III director at the meeting, and his chairmanship will take effect assuming he is re-elected. “Last quarter we were delighted to have appointed Robert Cardillo and Bill Scannell to our Board of Directors. In addition, the Board unanimously appointed Peter Chapman to serve as its next Chairman following the annual meeting given his half-decade worth of contributions to IonQ and his strong progress transitioning IonQ from an academic to a commercial company,” said Niccolo de Masi, Chairman of the Nominating & Corporate Governance Committee of IonQ’s Board. “Unde
Sealing System launches: XIO – Intelligent Farming26.4.2024 12:17:00 CEST | Press release
XIO – Intelligent Farming, specializes in logistics systems for insect protein production. XIO is a new business unit within Sealing System A/S, one of the leading providers of automated end-of-line packaging lines in Scandinavia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240426832303/en/ Robotic solution handling Black Soldier Fly Larvae (Photo: Business Wire) “At Sealing System A/S, we believe that practical innovation is the engine of real-world change. With the establishment of, XIO - Intelligent Farming, we are setting new industry standards, emphasizing the importance of intralogistics in the field of insect protein production, and proudly leading the way.” Ole Jensen CEO, Sealing System A/S XIO – Intelligent Farming provides solutions serving various aspects of the insect production, including fully automatic logistics systems, comprehensive data tracking, transfer trolleys and shuttles, as well as robot systems
Tecnotree Achieves Strong Q1 2024 Results with Sustained Revenue Growth and Enhanced Profitability26.4.2024 10:46:00 CEST | Press release
Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced its financial results for the first quarter of 2024, demonstrating solid growth with a 4.7% increase in revenue. The company maintained its momentum in driving global sales of its digital platform, in the first quarter of 2024, completing many AIML and digital transformations to key customers, resulting in a significant increase in revenue. The growth was primarily driven by new wins in the LATAM region, while EMEA and APAC regions remain growing markets for the digital platform. Key Q1 Highlights of the financial results: Net sales increased 4.7% to EUR 16.3 (15.5) million. Operating results increased by 22.3% to EUR 4.4 (3.6) million. Earnings per share EUR 0.01 (0.01). Order book at the end of the period increased by 10.3% to EUR 74.8 (67.8) million. Tecnotree achieved several notable milestones in the first quarter. The company solidified its position as a trusted par